The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Maintaining Safety with SARS-CoV-2 Vaccines
Open accessAbstract
The following table lists substances, other than active ingredients (i.e., antigens), shown in the manufacturers' package insert (PI) as being contained in the final formulation of each vaccine.Substances used in the manufacture of a vaccine but not listed as contained in the final product (e.g., culture media) can be found in each PI, but are not shown on this table.Each PI, which can be found on the FDA's website (see below) contains a description of that vaccine's manufacturing process, including the amount and purpose of each substance.In most PIs, this information is found in Section 11: "Description." Please refer to the PI for a complete list of ingredients or excipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
A global survey of potential acceptance of a COVID-19 vaccine
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S., & El-Mohandes, A. (2021) · Nature Medicine · doi:10.1038/s41591-020-1124-9 · Cited by 2,904
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Freeman, D. H., Loe, B. S., Chadwick, A., Vaccari, C., Waite, F., Rosebrock, L. E., Jenner, L., Petit, A., Lewandowsky, S., Vanderslott, S., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720005188 · Cited by 802
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Stone, C. A., Liu, Y., Relling, M. V., Krantz, M. S., Pratt, A. L., Abreo, A. M., Hemler, J. A., & Phillips, E. J. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.12.003 · Cited by 349
Bochner, B. S., & Lichtenstein, L. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106203242506 · Cited by 324
Cited by
Sorted by citations
Items 101–200 of 395
Greenhawt, M., Abrams, E. M., Oppenheimer, J. J., Leek, T. K. V., Mack, D. P., Singer, A. G., & Shaker, M. S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.01.022 · Cited by 36
“These features have included a number of highly subjective symptoms, which may be explained at least in part through a vasovagal or non-immune-mediated mechanism.(1,2) Although anaphylaxis is not a requirement for epinephrine use, similarly a response to epinephrine does not necessarily imply the presence of an allerg…”
Heldman, M. R., & Limaye, A. P. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021010023 · Cited by 35
Is complement the culprit behind COVID-19 vaccine-related adverse reactions?
Mastellos, D. C., Skendros, P., & Lambris, J. D. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151092 · Cited by 35
Xu, T., Zheng, W., & Huang, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.012 · Cited by 35
Leek, T. K. V., Chan, E. S., Connors, L. A., Dérfalvi, B., Ellis, A. K., Upton, J. E. M., & Abrams, E. M. (2021) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-021-00529-2 · Cited by 34
Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H., & Wei, D. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00438-3 · Cited by 34
Desai, A. P., Desai, A. P., & Loomis, G. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.058 · Cited by 34
Lin, W., Hu, K., Li, C., Pu, W., Yan, X., Chen, H., Hu, H., Deng, H., & Zhang, J. (2022) · Advanced Materials · doi:10.1002/adma.202204455 · Cited by 33
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Yoo, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e54 · Cited by 33
Li, L., Robinson, L. B., Patel, R. K., Landman, A., Fu, X., Shenoy, E. S., Hashimoto, D. M., Banerji, A., Wickner, P. G., Samarakoon, U., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.31034 · Cited by 35
van Vliet, V. J. E., Huynh, N., Palà, J., Patel, A., Singer, A. U., Slater, C., Chung, J., van Huizen, M., Teyra, J., Miersch, S., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1011065 · Cited by 35
“Despite the rapid approval of effective vaccines, the COVID-19 pandemic caused by SARSCoV-2 continues to affect human health across the globe more than 3 years after its emergence [1,2].”
BackgroundThe intestinal microbiota and improving the efficacy of COVID-19 vaccinations
Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32
Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
Somiya, M., Mine, S., Yasukawa, K., & Ikeda, S. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.066 · Cited by 32
Monforte, A. D., Tavelli, A., Perrone, P. M., Zà, A., Razzini, K., Tomasoni, D., Bordoni, V., Romanò, L., Orfeo, N. V., Marchetti, G. C., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100914 · Cited by 33
Weber, D. J., Al‐Tawfiq, J. A., Babcock, H. M., Bryant, K. A., Drees, M. L., Elshaboury, R. H., Essick, K., Fakih, M. G., Henderson, D. K., Javaid, W., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.322 · Cited by 33
The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women
Wang, P., Lee, W.-L., Yang, S., Tsui, K., Chang, C., & Lee, F. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000612 · Cited by 31
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
Laurini, G. S., Montanaro, N., Broccoli, M., Bonaldo, G., & Motola, D. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.054 · Cited by 31
“There is therefore no prior experience that informs the likelihood or explains the mechanism of allergic reactions with mRNA vaccines [31].”
Familial thrombocytopenia flare‐up following the first dose of mRNA ‐1273 Covid ‐19 vaccine
Toom, S., Wolf, B., Avula, A., Peeke, S. Z., & Becker, K. D. (2021) · American Journal of Hematology · doi:10.1002/ajh.26128 · Cited by 30
“These spike proteins are displayed by the antigen presenting cells leading to T-cell and B-Cell mediated immunity.(5) The Coronavirus efficiency (COVE) trial, a phase 3, randomized controlled, multicenter trial demonstrated 94.”
BackgroundRNA therapeutics for cardiovascular disease
Boada, C., Sukhovershin, R. A., Pettigrew, R. I., & Cooke, J. P. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000850 · Cited by 31
Coronavirus Disease 2019: Clinics, Treatment, and Prevention
Burkert, F. R., Lanser, L., Bellmann‐Weiler, R., & Weiß, G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.761887 · Cited by 30
Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13819-5 · Cited by 32
Ring, J., Worm, M., Wollenberg, A., Thyssen, J. P., Jakob, T., Klimek, L., Bangert, C., Barbarot, S., Bieber, T. R. M., de Bruin-Weller, M. S., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17237 · Cited by 29
Kashir, J., Ambia, A. R., Shafqat, A., Sajid, M. R., AlKattan, K. M., & Yaqinuddin, A. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5covr0621-320rr · Cited by 31
Ionic co-aggregates (ICAs) based oral drug delivery: Solubilization and permeability improvement
Zheng, X., Fang, Z., Huang, W., Qi, J., Dong, X., Zhao, W., Wu, W., & Lü, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.011 · Cited by 29
Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine
Julian, J. A., Mathern, D. R., & Fernando, D. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.02.011 · Cited by 28
Chan, Y., Ng, S. W., Singh, S. K., Gulati, M., Gupta, G., Chaudhary, S. K., Hing, G. B., Collet, T., MacLoughlin, R. J., Löbenberg, R., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119744 · Cited by 27
Medicinal chemistry insights into antiviral peptidomimetics
Ding, D., Xu, S., da Silva‐Júnior, E. F., Liu, X., & Zhan, P. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103468 · Cited by 28
COVID-19 Vaccine–Associated Takotsubo Cardiomyopathy
Jani, C., Leavitt, J. I., Omari, O. A., Dimaso, A., Pond, K. K., Gannon, S. A., Chandran, A. K., Dennis, C. R., & Colgrove, R. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001379 · Cited by 27
A Review of Pharmaceutical Robot based on Hyperspectral Technology
Su, X., Wang, Y., Mao, J., Chen, Y., Yin, A., Zhao, B., Zhang, H., & Liu, M. (2022) · Journal of Intelligent & Robotic Systems · doi:10.1007/s10846-022-01602-7 · Cited by 27
mRNA COVID-19 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation
Jaggers, J. L., & Wolfson, A. R. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01065-2 · Cited by 29
Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine
Marcelino, J. L. A., Farinha, S., Silva, R., Didenko, I., Proença, M., & Tomáz, E. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.022 · Cited by 26
“Hypersensitivity to the vaccine, or to one of its components, has generally been established as a contraindication to the vaccine administration.(1) Concerning the observed anaphylactic reactions, the pathophysiology remains to be determined.”
BackgroundMethodAllergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy
Kaplan, B. M., Farzan, S., Coscia, G. T., Rosenthal, D. W., McInerney, A., Jongco, A. M., Ponda, P., & Bonagura, V. R. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.10.019 · Cited by 26
The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review
Halma, M. T. J., Rose, J., Jenks, A., & Lawrie, T. A. (2023) · J — Multidisciplinary Scientific Journal · doi:10.3390/j6020017 · Cited by 25
“Several of the assumptions have been either challenged or overturned by experimental [53] and clinical evidence [54].”
BackgroundDrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing
Bejan, C. A., Cahill, K. N., Staso, P. J., Choi, L., Peterson, J. F., & Phillips, E. J. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2376 · Cited by 24
Large-vessel giant cell arteritis after COVID-19 vaccine
Mejren, A. H. J., Sørensen, C., Gormsen, L. C., Tougaard, R. S., & Nielsen, B. (2021) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2021.1961401 · Cited by 25
“Despite the fact that the mRNA COVID-19 vaccine from Pfizer-BioNTech contains lipid-based nanoparticles, it is considered essentially adjuvant free (4, 5) Hence, in our case, the mRNA vaccine itself, rather than its excipients, may have triggered GCA onset.”
BackgroundVesin, B., Lopez, J., Noirat, A., Authié, P., Fert, I., Chevalier, F. L., Moncoq, F., Nemirov, K., Blanc, C., Planchais, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.016 · Cited by 24
“In this context, the safety and potential adverse effects of multiple additional homologous doses of the first-generation COVID-19 vaccines, for instance related to allergic reaction to polyethylene glycol contained in mRNA vaccines, have to be considered.(13) Importantly, a heterologous prime boost vaccine delivery m…”
Visual Detection of COVID-19 from Materials Aspect
Wang, G., Wang, L., Meng, Z., Su, X., Jia, C., Qiao, X., Pan, S., Chen, Y., Cheng, Y., & Zhu, M. (2022) · Advanced Fiber Materials · doi:10.1007/s42765-022-00179-y · Cited by 25
RNA Therapeutics: A Healthcare Paradigm Shift
Niazi, S. K. (2023) · Biomedicines · doi:10.3390/biomedicines11051275 · Cited by 25
“Poly sarcosine-conjugated lipids have been developed as an alternative [63].”
BackgroundBeeraka, N. M., Tulimilli, S. V., Karnik, M., Sadhu, S. P., Pragada, R. R., Aliev, G., & Madhunapantula, S. V. (2021) · BioMed Research International · doi:10.1155/2021/8160860 · Cited by 25
“Anaphylaxis is a serious adverse reaction that can foster asphyxiation, cardiovascular collapse, and multiorgan dysfunction, and sometimes may lead to death [212].”
BackgroundLin, C.-A., Ho, H., Venkatesan, P., Huang, C., Cheng, Y.-J., Lin, Y.-H., Lin, H.-Y., Chen, T.-Y., Huang, M., & Lai, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101569 · Cited by 24
“The Centers for Disease Control and Prevention has recommended the administration of the Pfizer/BioNTech and Moderna COVID-19 vaccines, and exclusion of any person who has a history of allergic reaction associated with any of the vaccine components, including PEG and PEG derivatives, such as excipient polysorbates as…”
MethodCopaescu, A. M., Duque, J. S. R., & Phillips, E. J. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.03.030 · Cited by 24
“This raised concern that these reactions could be immunoglobulin (Ig)E mediated with allergen crosslinking on mast cells and rapid improvement following epinephrine administration.(5) If this was the case, reactions would be expected to repeat and intensify on subsequent reactions, which fortunately was not the case.”
InfluentialMouri, M., Imamura, M., Suzuki, S., Kawasaki, T., Ishizaki, Y., 櫻井恵一, Nagafuchi, H., Matsumura, N., Uchida, M., Ando, T., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.05.007 · Cited by 24
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
Ngo, C., Fried, W., Aliyari, S. R., Feng, J. J., Qin, C., Zhang, S., Yang, H., Shanaa, J., Feng, P., Cheng, G., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00810 · Cited by 23
Wang, C. Y., Rademaker, M., Tate, B. J., Baker, C., & Foley, P. A. (2021) · Australasian Journal of Dermatology · doi:10.1111/ajd.13593 · Cited by 23
“reactions to BNT162b2 were reported in patients with significant history of anaphylaxis.(5) Widespread use of the vaccine so far suggests that severe allergic reactions are very rare, with initial reported rates of around 1–2 in 100 000 doses.”
BackgroundMorena, F., Argentati, C., Tortorella, I., Emiliani, C., & Martino, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136874 · Cited by 23
D’Amelio, R., Asero, R., Cassatella, M. A., Laganà, B., Lunardi, C., Migliorini, P., Nisini, R., Parronchi, P., Quinti, I., Racanelli, V., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9091163 · Cited by 22
“mRNA coding for the Spike protein of SARSCoV-2 is delivered in lipid nanoparticles to favor its entry into the cell and to protect it from circulating and tissue RNAses [46,47].”
BackgroundNaidoo, N. S., Azar, A. J., Khamis, A. H., Gholami, M., Lindsbro, M., Alsheikh-Ali, A. A. A., & Banerjee, Y. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.726814 · Cited by 26
“Social distancing is the effectual preventive strategy since the emergence of COVID-19, pending completion of vaccination, treatment, or both (5, 6).”
BackgroundMethodSong, S., Kim, H., Jang, E. Y., Jeon, H.-M., Diao, H., Khan, M. R. I., Lee, M., Lee, Y. J., Nam, J., Kim, S., et al. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13908 · Cited by 24
“However, mRNA-based vaccines appear to cause more side effects than conventional vaccines (Castells and Phillips, 2021).”
BackgroundMustafa, Z. U., Bashir, S., Shahid, A., Raees, I., Salman, M., Merchant, H. A., Aldeyab, M. A., Kow, C. S., & Hasan, S. S. (2022) · Viruses · doi:10.3390/v14112344 · Cited by 171
Chary, M. A., Barbuto, A. F., Izadmehr, S., Tarsillo, M., Fleischer, E., & Burns, M. M. (2023) · Journal of Medical Toxicology · doi:10.1007/s13181-023-00931-9 · Cited by 25
“Non-IgE mediated responses to the lipid or PEG are also possible [93].”
BackgroundAl-Mutairi, N., Almutairi, A. N., Almazyad, M., & Alwazzan, S. (2022) · Dermatologic Therapy · doi:10.1111/dth.15521 · Cited by 23
“Topmost within these vaccines are the messenger RNA (mRNA) constructed vaccines, which are promising new technology against SARS-CoV-2 infection.(55) BNT162b2 became the first vaccine to be approved for emergency use.”
BackgroundA Novel Development of Sarcoidosis Following COVID-19 Vaccination and a Literature Review
Numakura, T., Murakami, K., Tamada, T., Yamaguchi, C., Inoue, C., Ohkouchi, S., Tode, N., Sano, H., Aizawa, H., Sato, K. A., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0104-22 · Cited by 22
“BNT162b2 also had a favorable safety profile characterized by transient mild-to-moderate injection-site pain, fatigue, and headache, with the only notable exception being potentially immune-mediated autoimmune thrombosis and myocarditis (7-9).”
BackgroundUtilizing Biologics in Drug Desensitization
Yang, B. C., & Castells, M. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01052-z · Cited by 22
Characteristics and outcomes of adverse events after COVID‐19 vaccination
Kewan, T. Z., Flores, M., Mushtaq, K., Alwakeel, M. I., Burton, R., Campbell, J., Perry, H., Al‐Jaghbeer, M. J., & Fadel, F. A. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12565 · Cited by 20
Almohaya, A. M., Qari, F., Zubaidi, G. A., Alnajim, N., Moustafa, K., Alshabi, M. M., Alsubaie, F. M., Almutairi, I. M. M., Alwazna, Q., Al‐Tawfiq, J. A., et al. (2021) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2021.101595 · Cited by 21
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Fernandes, A., Chaudhari, S., Jamil, N., & Gopalakrishnan, G. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.01.013 · Cited by 19
Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer
Kuderer, N. M., Hill, J. A., Carpenter, P. A., & Lyman, G. H. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1885596 · Cited by 20
Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide
Kunzelmann, K. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100094 · Cited by 20
“Although the UK and USA monitoring systems, Yellow card and VAERS do not show an unusual number of adverse reactions or fatal outcome by Sars-Cov-2 vaccines [7,8], there are serious issues related to safety and decreased efficacy of the vaccines in older patients [9], allergic reactions and antibody-dependent enhancem…”
BackgroundSeptic Arthritis of the Shoulder After SARS-CoV-2 Pfizer Vaccination
Massel, D. H., Haziza, S., Rivera, S., Mohile, N. V., Subhawong, T. K., & Hernandez, V. H. (2021) · JBJS Case Connector · doi:10.2106/jbjs.cc.21.00090 · Cited by 21
Holmes, G. A., Desai, M., Limone, B. A., Love, J., Tawfik, M., Wong, L., & Furukawa, B. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.07.038 · Cited by 20
“19- 7 cases with the Pfizer vaccine and 9 cases with the Moderna vaccine.(7,8) A now well-documented cutaneous manifestation of COVID-19 vaccination is a delayed local reaction that occurs within a median of 8 days of vaccine administration, presenting with an erythematous, edematous plaque.”
Arroliga, M. E., Dhanani, K., Arroliga, A. C., Huddleston, P. S., Trahan, J., Aguilar, T., & Weldon, D. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210069 · Cited by 20
Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy
Banerji, A., Norton, A. E., Blumenthal, K. G., Stone, C. A., & Phillips, E. J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.023 · Cited by 20
“This led to the hypothesis that the polyethylene glycol (PEG)-2000 molecule, which stabilizes the lipid nanoparticle carrier of the active mRNA encoding the severe acute respiratory syndrome coronavirus 2 spike protein, could be the culprit antigen triggering these COVID-19 mRNA vaccines’ immediate allergic reactions.…”
BackgroundAdverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy
Inoue, S., Igarashi, A., Morikane, K., Hachiya, O., Watanabe, M., Kakehata, S., Sato, S., & Ueno, Y. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.11.007 · Cited by 19
“However, there is a risk for adverse reactions to vaccination, and various adverse reactions have been reported with the COVID-19 vaccine [9].”
BackgroundGarcia-Grimshaw, M. A., Galnares‐Olalde, J. A., Bello‐Chavolla, O. Y., Michel‐Chávez, A., Cadena‐Fernández, A., Briseño‐Godínez, M. E., Antonio‐Villa, N. E., Núñez, I., Gutiérrez, A., Hernández‐Vanegas, L. E., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15504 · Cited by 19
“the lipid nanoparticles required to prevent enzymatic degradation of mRNA particles may be a trigger for GBS in genetically or environmentally susceptible individuals [50, 51].”
BackgroundGraves’ Disease Following SARS-CoV-2 Vaccination: A Systematic Review
Patrizio, A., Ferrari, S. M., Elia, G., Ragusa, F., Paparo, S. R., Mazzi, V., Antonelli, A., & Fallahi, P. (2022) · Vaccines · doi:10.3390/vaccines10091445 · Cited by 20
“As with other vaccinations, the anti-SARS-CoV-2 vaccination campaign immediately highlighted the possibility of developing side effects, ranging from mild local reactions (pain at the insertion point) to systemic phenomena (fever, headache, asthenia, muscle aches) [6].”
BackgroundUsing motivational interviewing techniques to inform decision-making for COVID-19 vaccination
Zolezzi, M., Paravattil, B., & El-Gaili, T. (2021) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01334-y · Cited by 19
“Vaccines usually contain lipids that help deliver the mRNA into the cells and other common ingredients that help maintain the pH and stability of the vaccine [28].”
BackgroundWorsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination
Patrizio, A., Ferrari, S. M., Antonelli, A., & Fallahi, P. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103096 · Cited by 19
“Since the end of 2020, vaccines against SARS-CoV-2 have been released and predictable adverse events such as fever, fatigue, headache, muscle and joint pain or anaphylaxis have been documented [1].”
Bellanti, J. A. (2021) · Allergy and Asthma Proceedings · doi:10.2500/aap.2021.42.210063 · Cited by 18
Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 17
Chung, W., Preclaro, I. A. C., Chung, W., & Wang, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061260 · Cited by 18
Yon, M., Gibot, L., Gineste, S., Laborie, P., Bijani, C., Mingotaud, C., Coutelier, O., Desmoulin, F., Pestourie, C., Destarac, M., et al. (2023) · Nanoscale · doi:10.1039/d2nr04691a · Cited by 18
A reasoned approach towards administering COVID‐19 vaccines to pregnant women
Pramanick, A., Kanneganti, A., Wong, J. L. J., Li, S. W., Dimri, P. S., Mahyuddin, A. P., Kumar, S., Illanes, S. E., Chan, J. K. Y., Su, L., et al. (2021) · Prenatal Diagnosis · doi:10.1002/pd.5985 · Cited by 19
“Safety surveillance systems should be maintained by public health bodies, professional medical organisations or healthcare fa- cilities at a local, regional or national level with attention to pregnant women172,173 such as the UK Obstetric Surveillance System (UKOSS)/UK Teratology Information Service (UKTIS) and the C…”
BackgroundOsada, A., Sakuragi, C., Toya, C., & Mitsuo, A. (2021) · Internal Medicine · doi:10.2169/internalmedicine.8651-21 · Cited by 18
“speculated to be the major cause of anaphylaxis to BNT162 b2 (20), and acute infusion reactions have been reported as”
BackgroundHorn, M. P., Jónsdóttir, H. R., Brigger, D., Damonti, L., Suter‐Riniker, F., Endrich, O., Froehlich, T. K., Fiedler, M., Largiadèr, C. R., Marschall, J., et al. (2022) · Allergy · doi:10.1111/all.15206 · Cited by 21
“Problematically, manufacturers of serological assays often provide diagnostic accuracy data generated through biased studies and claiming to have a sensitivity and specificity close to 100% [2, 5, 12] [17] [2, 10, 13, 18, 19].”
BackgroundA New Role for Old Friends: Effects of Helminth Infections on Vaccine Efficacy
Zhu, F., Liu, W., Liu, T., Shi, L., Zheng, W., Guan, F., & Lei, J. (2022) · Pathogens · doi:10.3390/pathogens11101163 · Cited by 17
“In addition, it has been reported that the first dose of a COVID-19 vaccine is attributed to non-immunoglobulin E (IgE)-mediated mast cell activation by vaccine excipients [75].”
BackgroundEvaluation of Adverse Reactions to Vaccines
Roches, A. D., Graham, F. J., Bégin, P., Paradis, L. P., & Gold, M. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.08.002 · Cited by 17
Su, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 15
Vaccine-induced thrombotic thrombocytopenia following coronavirus vaccine: A narrative review
Ahmed, S. H., Shaikh, T. G., Waseem, S., Qadir, N. A., Yousaf, Z., & Ullah, I. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102988 · Cited by 17
“These vaccines are now widely available for public administration [4].”
Pitlick, M. M., Sitek, A. N., D’Netto, M. E., Dages, K. N., Chiarella, S. E., Gonzalez‐Estrada, A., Joshi, A. Y., & Park, M. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.11.006 · Cited by 16
Discrete polyethylene glycol derivatives as a potent impetus for next-generation biomedicines
Cen, J., Hou, M., & Liu, S. (2023) · Giant · doi:10.1016/j.giant.2023.100169 · Cited by 16
Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review
Sabato, V., Michel, M., Blank, U., Ebo, D. G., & Vitte, J. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000768 · Cited by 16
Neuroleptic malignant syndrome following COVID-19 vaccination
Alfishawy, M., Bitar, Z. I., El-Gazzar, A., & Elzoueiry, M. M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.02.011 · Cited by 16
“COVID-19 is known to have many neurological complications ranging from anosmia to encephalomyelitis, seizures, and stroke [6] Although mRNA vaccines were found generally safe in clinical trials [5] apart from anaphylaxis and the few cases of Bell's palsy but the immune activation associated with such vaccines could ha…”
Song, J., Su, D., Wu, H., & Guo, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060798 · Cited by 18
Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 16
The Immune Responses against Coronavirus Infections: Friend or Foe?
Vafaeinezhad, A., Atashzar, M. R., & Baharlou, R. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000516038 · Cited by 15
The type of SARS‐CoV‐2 vaccine influences serological response in kidney transplant recipients
Correia, A. L., Leal, R. G. C., Pimenta, A. C., FERNANDES, M. R., Marques, M. G., Rodrigues, L., Santos, L., Romãozinho, C., Sá, H., Pratas, J., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14585 · Cited by 15
Gümüşburun, R., Dalgıç, C. T., Mete, N., & Sin, A. Z. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524099 · Cited by 15
Incidence and management of the main serious adverse events reported after COVID ‐19 vaccination
Padilla‐Flores, T., Sampieri, A., & Vaca, L. A. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1224 · Cited by 17
“74 The mechanisms involved in vaccine-induced anaphylaxis have not been elucidated but are of special interest, as vaccine platforms that have been associated with anaphylactic cases are those more recently approved for use in humans (mRNA and viral vectors).”
BackgroundInfluentialRBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2
Feng, R., Xue, R., Liu, C., Li, G.-C., Deng, Y., Jin, Z., Liu, J.-Y., Zhang, S., Cheng, H., Guo, M., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03191-7 · Cited by 16
Alania-Torres, E., Morillas-Climent, H., García-Escrivá, A., Vinueza-Buitrón, P., Catalá, I. P., Zorio, E., Sánchez-Lázaro, I. J., Galcerá-Jornet, E., & Valle-Muñoz, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.759119 · Cited by 15
“Pfizer-BioNTech and Moderna Covid-19 vaccines (both mRNA) have significantly contributed to get the pandemic under control (1).”
BackgroundMaternal COVID-19 Vaccination and Its Potential Impact on Fetal and Neonatal Development
Karrow, N. A., Shandilya, U. K., Pelech, S., Wagter-Lesperance, L., McLeod, D., Bridle, B. W., & Mallard, B. A. (2021) · Vaccines · doi:10.3390/vaccines9111351 · Cited by 15
“Anaphylaxis is one AVR that is associated with the COVID-19 mRNA vaccines [27], and for the Pfizer–BioNTech vaccine, the risk is 1:100,000 [28].”
BackgroundChemo-Enzymatic PEGylation/POxylation of Murine Interleukin-4
Haas, D., Hauptstein, N., Dirauf, M., Drießen, M. D., Ruopp, M., Schubert, U. S., Lühmann, T. C., & Meinel, L. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00495 · Cited by 15
COVID-19 vaccine trials must include helminth-infected cohorts
Egwang, T. G., Owalla, T. J., & Kemigisha, M. (2022) · Nature Immunology · doi:10.1038/s41590-021-01116-8 · Cited by 15
Tumor Antigen-Based Nanovaccines for Cancer Immunotherapy: A Review
Zhao, J., Du, G., & Sun, X. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3178 · Cited by 15
Acute thyroid swelling with severe hypothyroid myxoedema after COVID‐19 vaccination
Giusti, M., & Maio, A. (2021) · Clinical Case Reports · doi:10.1002/ccr3.5217 · Cited by 14
Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review
Oueijan, R. I., Hill, O. R., Ahiawodzi, P. D., Fasinu, P. S., & Thompson, D. K. (2022) · Medicines · doi:10.3390/medicines9080043 · Cited by 14
“It has been hypothesized that the polyethylene glycol (PEG)-conjugated lipid derivative in the formulation of the SARS-CoV-2 mRNA vaccines may be an antigen for anaphylaxis and nonanaphylactic reactions [78].”
BackgroundA SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag
Yan, W., Yu, W., Shen, L., Xiao, L., Qi, J., & Hu, T. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127159 · Cited by 15
Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review
Sanyaolu, A. O., Okorie, C., Marinkovic, A., Prakash, S., Williams, M., Haider, N., Mangat, J., Hosein, Z., Balendra, V., Abbasi, A. F., et al. (2022) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355221097559 · Cited by 14
Engineering of Biodegradable and Excretable Inflammation‐Resolving Materials
Wu, P., Gao, M., Zhang, C., Li, C., Li, G., Yan, X., Lai, X., Zhang, Y., & Zhang, J. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202205528 · Cited by 14
Metadata
- Authors
- Castells, M. C., & Phillips, E. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Castells, Mariana C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-18
- Volume
- 384
- Issue
- 7
- Pages
- 643-649
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787218
- OpenAlex
- W3115737775
- Cited by
- 395
- References
- 17
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 24 · 2023: 42 · 2022: 114 · 2021: 189
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccines, vaccine excipients, vaccine ingredients, package inserts, vaccine safety, vaccine production
- MeSH terms
- COVID-19, COVID-19 Vaccines, mRNA Vaccines, Anaphylaxis, Humans, Vaccines, Synthetic, Viral Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
